Clinical studies, including the STEP 1 extension trial with semaglutide 2.4 mg, have shown that patients often regain a significant proportion of weight lost during GLP-1 therapy, typically over several months
For a 250-pound person, that is over 60 pounds
Regulatory Approvals : Gland holds USFDA, EU, WHO, and MHRA approvals, allowing access to global markets
However, the cost of these medications can be a barrier for many, making it essential to understand what drives their pricing and how patients can access them affordably
During that time, I have also seen vitamin and nutrient deficiencies associated with that significant weight loss, which have now become commonplace due to the unprecedented effectiveness of the new GLP-1 medications, said Aronne